This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fox, R. Articles by Krubel, S. Search for Related Content PubMed PubMed Citation Articles by Fox, R. Articles by Krubel, S. Social Bookmarking                         What's this?

Treatment of primary Sjögren's syndrome with hydroxychloroquine : a retrospective, open-label study

Division of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, California, USA

R. Dixon

Division of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, California, USA

V. Guarrasi

Division of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, California, USA

S. Krubel

Division of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, California, USA

Objectives: To determine whether patients with primary Sjögren's syndrome (SS), diagnosed according to San Diego criteria, had improvement in their laboratory or clinical features during treatment with hydroxychloroquine (6-7 mg/kg/day) for at least two years.,

Methods : The study population included 50 consecutive patients with primary SS who were diagnosed according to San Diego criteria, and in whom hydroxychloroquine was suggested as treatment. This group included 10 patients who were early dropouts (side effects or desire not to take antimalarial drugs) and 40 patients who received drugs for at least two years (range 24-48 months). In a subset of SS patients, values for ESR (westergren) and quantitat ive immunoglobulins were available for comparison. Improvement with therapy was defined as: (a) 20% improvement in variables of tear flow (Schirmer's test I) or corneal integrity (rose Bengal): (b) 20% salivary function (flow rate); and (c) improvement in at least two of the following measures: physicians assessment of global disease activity by 20%, patient assessment of improvement in pain or fatigue by 20%, and ESR improved by 20 mm/ hr.

Results: In a retrospective study of SS patients who completed the trial, a significant improvement was noted in ocular symptoms (pain and dryness) in patients (55 and 57%) and improved corneal integrity (rose Bengal straining) in 53% of patients. The Schirmer's test was improved by 2 mm/5 minutes in 50% in patients. Improvement was noted in oral symptoms (pain and dryness) in patients (57 and 60%) and salivary flow rate was increased in 82% of patients. In a subset of SS patients evaluated, the ESR improved by 20 mm/hr in 17/32 patients (53%) and quantitative IgG level by 20% in 8/13 patients (61%). Phys ician global assessment of overall patient status and patient assessment of overall status indicated improvement in over 62% of patients.

Conclusion: In a retrospective study of patients fulfilling San Diego Criteria for SS, we found: (a) sustained improvement of local symptoms (painful eyes, painful mouth) and improvement of systemic manifestations (arthralgias and myalgias) after treatment with hydroxychloroquine 6-7 mg/kg/day over mean three-year follow-up; (b) laboratory analysis showed a significant improvement in their ESR and their quantitative IgG levels; (c) no significant late toxicity was observed in this study cohort. A prospective study of hydroxy chloroquine in patients fulfilling San Diego criteria for SS is indicated.

Key Words: Sjögren's syndrome • hydroxycloroquine • antimalarial

Lupus, Vol. 5, No. 1 suppl, S31-S36 (1996)
DOI: 10.1177/096120339600500108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D J Wallace Antimalarials--the 'real' advance in lupus Lupus, June 1, 2001; 10(6): 385 - 387. [PDF]